Compensation award — excluded from discretionary-purchase analysis.
Loading…
Traded Feb 5, 2026 · Filed Feb 6, 2026
The boss of Gilead Sciences sold $17.3M of Gilead Sciences shares. It was planned long ago, so it says very little.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$17,346,000
Shares × reported transaction price
98 days after results of Oct 30, 2025, 5 days before results of Feb 10, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $149.37 on Feb 5, 2026, at its 52-week high, after a 20% rise over the previous 30 trading days
52-week range $95.48 (Feb 10, 2025) to $149.37 (Feb 5, 2026), 100% of the way up, from 251 adjusted closes. 30 trading days earlier: $124.16 on Dec 22, 2025. Describes the past only, not a forecast
A WARN layoff notice covering 34 workers was filed in California on January 21, 2026.
From the official state WARN list, 15 days before the trade; 1 more notice by the company within 60 days. Shown for timing only; the two filings are separate
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +2.4% | −1.6% | +4.0% |
| 30 days | −3.7% | −2.5% | −1.2% |
| 90 days | −12.0% | +6.5% | −18.5% |
| 180 days | −12.3% | +11.4% | −23.7% |
Past results only. Not a forecast.
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.